Download Melanoma Tumor Specimens with BRAF mutation data

Melanoma Tumor Specimens with
BRAF mutation data
The BRAF gene encodes a serine/threonine protein kinase which is involved in regulation of the MAP Kinase/ERK signaling
pathways. These pathways play a key role in cell growth and proliferation. Somatic mutations of BRAF occur in high
frequency in melanoma cancers and are currently the focus of oncogene targeted therapies. The most common mutations
occur on codon 600, with an amino acid substitution of valine. These mutations result in enhance BRAF kinase activity and
an increased phosphorylation of downstream targets. BRAF mutations are present in more than 60% of melanomas.
Asterand routinely screens it melanoma specimens for BRAF mutations using a polymerase chain reaction (PCR) based assay
that uses allele-specific probes to identify the presence of BRAF V600E, V600K, V600D, V600R and V600M.
Are you interested in other specimens with mutation analysis? Asterand routinely screens colorectal cancer (KRAS) and lung
cancer (KRAS/EGFR) tumors. We also offer custom screening projects to fit your specific needs.
B-RAF MUTATIONS SCREENED
Mutation Name
Nucleotide Change
Amino Acid Change
V600E
c. 1799T>A
Valine (V) to glutamic acid (E)
V600K
c. 1798_1799GT>AA
Valine (V) to lysine acid (K)
V600D
c. 1799_1800TG>AT
Valine (V) to aspartic acid (D)
V600R
c. 1798_1799GT>AG
Valine (V) to arginine (R)
V600M
c. 1798G>A
Valine (V) to methionine (M)
INQUIRES can be made through
www.asterand.com and
advantage @asterand.com,
or by calling 1.866.384.7783.
Unless otherwise noted, all trademarks are the property of Stemgent Inc. 2013 Stemgent, Inc. All rights reserved.
www.asterand.com
Colorectal Tumor Specimens with
KRAS mutation data
The KRAS gene encodes a small GTPase that plays a key role in signal transduction from the epidermal growth factor
receptor (EGFR) to downstream effectors. EGFR is a membrane protein that plays a central role in transmitting signals
that promote cell growth and proliferation. KRAS mutations have been found to occur most commonly in several types of
cancers, most notably, metastatic colon cancer and lung adenocarcinomas. Tumors with mutant forms of the KRAS gene are
less likely to respond to anti-EGFR antibody therapies. The most common KRAS mutations are found on codons 12, 13 and
61.
Asterand routinely screens it colorectal cancer specimens for KRAS mutations using a polymerase chain reaction (PCR) based
assay that uses allele-specific probes to identify the presence of mutations in KRAS codons 12, 13 and 61.
Are you interested in other specimens with mutation analysis? Asterand routinely screens colorectal cancer (KRAS) and
melanoma (BRAF) tumors. We also offer custom screening projects to fit your specific needs.
KRAS MUTATIONS SCREENED
Nucleotide Change
Amino Acid Change
Amino Acid Change
(GGT>GCT)
G12A
Gly12Ala
(GGT>GAT)
G12D
Gly12Asp
(GGT>CGT)
G12R
Gly12Arg
(GGT>TGT)
G12C
Gly12Cys
(GGT>AGT)
G12S
Gly12Ser
(GGT>GTT)
G12V
Gly12Val
(GGC>GAC)
G13D
Gly13Asp
(CAA>CAC)
Q61H
Gln61His
(CAA>CAT)
Q61H
Gln61His
(CAA>CTA)
Q61L
Gln61Leu
(CAA>CGA)
Q61R
Gln61Arg
INQUIRES can be made through
www.asterand.com and
advantage @asterand.com,
or by calling 1.866.384.7783.
Unless otherwise noted, all trademarks are the property of Stemgent Inc. 2013 Stemgent, Inc. All rights reserved.
www.asterand.com
Lung Tumor Specimens with KRAS
and EGFR mutation data
The most common oncogene mutations in lung cancer occur within KRAS and EGFR. The KRAS gene encodes a small GTPase
that plays a key role in signal transduction from the epidermal growth factor receptor (EGFR) to downstream effectors.
EGFR is a membrane protein that plays a central role in transmitting signals that promote cell growth and proliferation.
Mutations in the EGFR, KRAS and anaplastic lymphoma kinase (ALK) are mutually exclusive in patients with non-small
cell lung cancer and the presence of any one of these mutations can influence response to targeted therapies. The most
common KRAS mutations are found on codons 12, 13 and 61. EGFR mutations are most commonly located on Exons 18, 19,
20 and 21.
Asterand routinely screens it lung cancer specimens for KRAS and EGFR mutations using a polymerase chain reaction (PCR)
based assay that uses allele-specific probes to identify the presence of these mutations (see listing below).
Are you interested in other specimens with mutation analysis? Asterand routinely screens colorectal cancer (KRAS) and
melanoma (BRAF) tumors. We also offer custom screening projects to fit your specific needs.
EGFR MUTATIONS SCREENED
Exon 18
Exon 19
G719A - 2156G>C
2235 - 2249 del 15
G719S - 2155G>A
2235 - 2252>AAT del 18
G719C - 2155G>T
Exon 20
Exon 21
2238 - 2248>GC del 11
T790M-2369C>T
L858R - 2573T>G
2238 - 2252>GCA del 15
S768I - 2303G>T
L861Q - 2582T>A
2236 - 2253 del 18
2239 - 2247 del 9
2307 - 2308 ins GCCAGCGTG
2237 - 2251 del 15
2239 - 2253 del 15
319 - 2320 ins CAC
2237 - 2254 del 18
2239 - 2256 del 18
2310 - 2311 ins GGT
2237 - 2255>T del 19
2239 - 2248>C del 10
2236 - 2250 del 15
2239 - 2258>CA del 20
2238 - 2255 del 18
2240 - 2251 del 12
KRAS MUTATIONS SCREENED
Nucleotide Change
Amino Acid Change
Amino Acid Change
- Expanded
(GGT>GCT)
G12A
Gly12Ala
(GGT>GAT)
G12D
Gly12Asp
(GGT>CGT)
G12R
Gly12Arg
(GGT>TGT)
G12C
Gly12Cys
(GGT>AGT)
G12S
Gly12Ser
(GGT>GTT)
G12V
Gly12Val
(GGC>GAC)
G13D
Gly13Asp
(CAA>CAC)
Q61H
Gln61His
(CAA>CAT)
Q61H
Gln61His
(CAA>CTA)
Q61L
Gln61Leu
(CAA>CGA)
Q61R
Gln61Arg
Unless otherwise noted, all trademarks are the property of Stemgent Inc. 2013 Stemgent, Inc. All rights reserved.
www.asterand.com
INQUIRES can be made through
www.asterand.com and
advantage @asterand.com,
or by calling 1.866.384.7783.